SCHEMBL5544803

SCHEMBL5544803

CCn1cc(C(=O)O)c(=O)c2ccc(Cl)cc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.57
HPGD P15428 5/20 0.57
HSD17B10 Q99714 4/20 0.57
ALDH1A1 P00352 4/20 0.57
TSHR P16473 3/20 0.57
RAB9A P51151 1/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2D6 P10635 1/20 0.57
APEX1 P27695 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
PIK3CG P48736 2/20 0.54
PIK3CD O00329 1/20 0.54
PIK3R1 P27986 1/20 0.54
PIK3CA P42336 1/20 0.54
LMNA P02545 5/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ABCC4 O15439 1/20 0.53
PKM P14618 1/20 0.53
PTGS1 P23219 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30906937 1.00 KDM4E (0.57) KDM4EHPGDHSD17B10ALDH1A1TSHR
SCHEMBL2642676 0.90 KDM4E (0.48) KDM4EHPGDHSD17B10ALDH1A1TSHR
SCHEMBL1366635 0.89 KDM4E (0.68) KDM4EHPGDHSD17B10ALDH1A1TSHR
SCHEMBL28117698 0.88 KDM4E (0.67) KDM4EHPGDHSD17B10ALDH1A1TSHR
SCHEMBL11400089 0.84 KDM4E (0.59) KDM4EHPGDHSD17B10ALDH1A1TSHR
SCHEMBL12674058 0.84 KDM4E (0.59) KDM4EHPGDHSD17B10ALDH1A1TSHR
SCHEMBL30906934 0.84 LMNA (0.63) KDM4EHPGDHSD17B10ALDH1A1TSHR
SCHEMBL30906936 0.84 LMNA (0.63) KDM4EHPGDHSD17B10ALDH1A1TSHR
SCHEMBL9151604 0.84 LMNA (0.63) KDM4EHPGDHSD17B10ALDH1A1TSHR
SCHEMBL5544795 0.84 LMNA (0.73) LMNAP2RX3CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453846-B1 14 OR 15 MEMBERED MACROLIDES WITH ANTIBACTERIAL ACTIVITY GLAXO GROUP LTD (GB) 2007-05-16 EP disclosed
US-7202221-B2 Macrolides GLAXO GROUP LIMITED (GB) 2007-04-10 US disclosed
CN-1307194-C Macrolides GLAXO GROUP LTD (GB) 2007-03-28 CN disclosed
CN-1612888-A Macrolides GLAXO GROUP LTD (GB) 2005-05-04 CN disclosed
US-20050080025-A1 Macrolides PLIVA D.D. (HR) 2005-04-14 US disclosed
US-5753659-A ANTICOAGULANTS FOR BLOOD DISORDER, CARDIOVASCULAR DISORDER, THROMBOSIS, ZENECA LIMITED (GB) 1998-05-19 US disclosed
US-5750754-A TERTIARY BUTYL 3-METHYL-4-SUBSTITUTED BUTYRATE; CHEMICAL INTERMEDIATES FOR ANTICAOGULANT DRUGS ZENECA LIMITED (GB) 1998-05-12 US disclosed
US-5563141-A INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION ZENECA LIMITED (GB) 1996-10-08 US disclosed
EP-0690847-A1 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1996-01-10 EP disclosed
WO-1994022835-A2 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1994-10-13 WO disclosed
EP-0607825-A1 6-H-4-OXO-3-quinoline-carboxylic acids and their analogues as antibacterial agents BAYER AG (DE) 1994-07-27 EP disclosed
US-4292317-A BACTERICIDES FOR GRAM NEGATIVE AND -POSITIVE BACTERIA; ANIMAL GROWTH REGULATORS LABORATORIE ROGER BELLON (FR) 1981-09-29 US disclosed
US-4017622-A BACTERICIDES DAINIPPON PHARMACEUTICAL CO., LTD. (JA) 1977-04-12 US disclosed
US-3953428-A ANTIBACTERIAL YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) 1976-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080025-A1 Macrolides IL17A, CYP51A1, IL15 KDM4E 2733/4885HPGD 2437/4885HSD17B10 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.